News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
ImaRx Therapeutics Cancels IPO Due To Market Conditions
December 6, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Dec 5 (Reuters) - ImaRx Therapeutics Inc. on Tuesday withdrew a planned initial public offering of 5 million shares for an estimated price of $10 to $12 each, citing unfavorable market conditions.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Gene therapy
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact
October 10, 2025
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novo Strikes up to $5.2B Deal for Akero in Red-Hot MASH Space
October 9, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
October 8, 2025
·
2 min read
·
Tristan Manalac
IPOs
UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio
October 7, 2025
·
3 min read
·
Tristan Manalac
